COMPANY OVERVIEW
PENMIX Your challenge, Our solution
Quick Facts • Annual Revenue : 46 Million USD (2015) +22% from 2014 • Field of Business
Penicillin Products General Injectables
CDMO
• Facilities
Factory 1: Penicillin specialized -
Largest capacity in Korea
-
Oral (tablet, Syrup) / Injectable (powder-filled, lyophilized vials)
Factory 2 : General Injectable -
Established in late 2013 with EU GMP, cGMP level
-
Lyophilized, Vials, PFS, Big vials, Powder
• Key Characteristics / Experiences -
NO. 1 Penicillin Manufacturer / supplier in Korea NO. 1 in Penicillin Injectables supplier in Japan (generic) Exports to +14 countries world wide
+10 years of Experience w/ Injectables (Lyophilized, vials)
HISTORY 2002 Separated from its parent Company Kuhnil pharma. Established its Headquarters in Korea.
2010 Designed concept for the new injectable plant (EU / cGMP grade)
Awarded for “Large and Small business Cooperation� by the Prime Minister
2004
2006
2008
Introduced equipment for injectable line with expansion of the factory.
Second expansion of the factory with additional equipment for the injectable line
Expanded export to Japanese market
Further expansion of the export to the Japanese market
2011
2013
Established the automated warehouse
Completed Injectable Factory construction
Initiated Injectable Factory construction .
GMP certification Approval for Injectable Factory by KFDA
Introduced Equipment for Solid dosage form production Award for achieving 10 million USD in Export
2014 Completed PreFilled Syringe line. Manufacturing initiated for General Inj. Factory
COMPANY OVERVIEW PENMIX = PENICILLIN + MIXTURE Specialized in manufacturing Penicillin and General Injectable Products as a CDMO
Penicillin
GENERAL INJECTABLE
▶ Specialized in finished penicillin products • Oral : Tablet, Dried Suspension • Injectable : Lyophilized, Powder filled Vial ▶ Approved by Japan as a foreign manufacturer
▶ Manufacturing facility established in 2013 • EU GMP, cGMP grade • KGMP Approval in November 2013 ▶ Capable of manufacturing Ampoule, Vial and PFS
Key Business Scope
The View of the Plants PENMIX
Penicillin Dedicated Factory
KUHNIL Pharm. Factory
PENMIX
General Injectable Factory
Manufacturing Capacity General Injectable Factory Production Line
Units
Lyophilizer 1 (300kg) Freeze dried (Lyophilized)
Lyophilizer 2 (500kg)
Vial (22Ø)
Lyophilizers 3 & 4 (600kg)
Current Annual Production Capacity Batch
Vial / Ampule / PFS
80
2,400,000
80
4,800,000
100
7,200,000
Powder
Vial (22Ø)
200
10,000,000
Ampoule
1mL Ampoule (11.2 Ø)
200
19,200,000
PFS
5mL Syringe (High Viscosity)
100
10,000,000 (5,000,000)
Penicillin Factory Production Line
Solids
Units
Current Annual Production Capacity Batch
Tablet / Bottle / Vial
Tablet
Tablet
600
300,000,000
Suspension
50mL Bottle
275
11,000,000
Powder
Vial (24Ø)
480
19,200,000
Lyophilized
Vial (24Ø)
162
6,480,000
Pipeline
GENERAL INJECTABLE Development schedule (tentative)
Anidulafungin Daptomycin (US)
Formulation study completed Formulation study in-progress
Glatiramer Micafungin Octreotide LAR Remifentanil Caspofungin Hyaluronic Acid
Glutathione Teicoplanin (KR) 2014
Vancomycin 2015
Dexmedetomidin
Palonosetron
Tigecycline(KR)
Voriconazole
2016
2017
Icatibant Paliperidone Teicoplanin (EU) 2018 and forward
Thank you. PENMIX Contact us at : Website: www.penmix.com Email : pexmixmail@kuhnil.com